Burgdorf - Ypsomed is pleased to announce that it has granted to a major, globally acting pharmaceutical company a non exclusive license to use certain patents, which protect inventions of Ypsomed in the area of auto-injector technology. Ypsomed expects to receive several million Swiss Francs in license fees over the term of the concluded agreement.
Burgdorf - After a phase of above average growth in sales and profit the Ypsomed Group is currently in a period of consolidation. In the frist half year 2006/07 (April 1 – September 1 2006) sales fell 8.8% to a total of CHF 129.0 million and a operating loss of CHF 5.3 million.
Burgdorf - Ypsomed today has to issue an ad-hoc information due to lower than expected orders for insulin pen systems. Therefore sales and profitability for the business year 2006/07 will be lower than forecasted so far. At the same time Ypsomed announced the change of the CEO.
Burgdorf - Ypsomed has substantially increased its production capacity over the last 24 months and is acquiring additional Ziegelmattareal property at Ypsomed's Solothurn site from Ascom for CHF 12.45 million with effect from 1st July 2006.